Biological production risk - disease outbreaks, water quality failures, or genetic performance shortfalls could render commercial operations unviable with limited recovery options in intensive aquaculture systems
Technology execution risk - land-based prawn farming at commercial scale remains unproven globally, with few successful precedents at target production densities and cost structures
Regulatory and environmental approval risk - aquaculture operations face stringent water discharge, biosecurity, and environmental impact requirements that could delay or prevent commercial operations
Market access risk - dependence on Asian export markets creates exposure to trade restrictions, biosecurity bans, or import quota changes
Competition from established pond-based prawn farming in Southeast Asia with lower capital intensity and proven economics at $3-5/kg production costs
Alternative protein sources including farmed whiteleg shrimp, wild-caught prawns, and plant-based seafood substitutes competing for consumer spending
Potential replication of technology by better-capitalized competitors if land-based model proves viable
Severe liquidity constraints with 0.62 current ratio indicating inability to meet short-term obligations without additional funding
High leverage at 3.44x debt/equity with negative equity returns (-209.5% ROE) suggesting balance sheet insolvency risk
Ongoing cash consumption with negative operating cash flow requiring continuous capital raises and creating dilution risk for existing shareholders
Asset impairment risk if development projects fail to achieve commercial viability, potentially writing off capitalized development costs
StructuralCompetitiveBalance Sheet